Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 3/20 | 0.42 |
| ▸ | CES1 | P23141 | 3/20 | 0.42 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.42 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | XBP1 | P17861 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.39 |
| ▸ | CXCR1 | P25024 | 2/20 | 0.39 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4065115 | 1.00 | CES2 (0.42) | CES2CES1BCAT2GPR139MAPT | |
| SCHEMBL4065108 | 1.00 | CES2 (0.42) | CES2CES1BCAT2GPR139MAPT | |
| SCHEMBL13990223 | 0.81 | POLB (0.51) | CES2CES1GPR139SMN1; SMN2LMNA | |
| SCHEMBL4871578 | 0.81 | POLB (0.51) | CES2CES1GPR139SMN1; SMN2LMNA | |
| SCHEMBL27607672 | 0.81 | POLB (0.51) | CES2CES1GPR139SMN1; SMN2LMNA | |
| SCHEMBL6575624 | 0.80 | SMN1; SMN2 (0.44) | CES2CES1GPR139MAPTSMN1; SMN2 | |
| SCHEMBL6578239 | 0.80 | SMN1; SMN2 (0.44) | CES2CES1GPR139MAPTSMN1; SMN2 | |
| SCHEMBL7546809 | 0.80 | SMN1; SMN2 (0.44) | CES2CES1GPR139MAPTSMN1; SMN2 | |
| SCHEMBL18113302 | 0.80 | KMT2A (0.50) | MAPTSMN1; SMN2LMNAKMT2AALDH1A1 | |
| SCHEMBL16044915 | 0.79 | MAPT (0.45) | CES2CES1GPR139MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12410262-B2 | Peptide conjugates of cytotoxins as therapeutics | Cybrexa 2, Inc. (US) | 2025-09-09 | — | — | US | disclosed |
| US-20240010755-A1 | PEPTIDE CONJUGATES OF CYTOTOXINS AS THERAPEUTICS | Cybrexa 2, Inc. | 2024-01-11 | — | — | US | disclosed |
| US-11634508-B2 | Peptide conjugates of cytotoxins as therapeutics | Cybrexa 2, Inc. (US) | 2023-04-25 | — | — | US | disclosed |
| US-11634508-B2 | Peptide conjugates of cytotoxins as therapeutics | Cybrexa 2, Inc. (US) | 2023-04-25 | — | — | US | disclosed |
| EP-3997093-A1 | PEPTIDE CONJUGATES OF CYTOTOXINS AS THERAPEUTICS | Cybrexa 2, Inc. (US) | 2022-05-18 | — | — | EP | disclosed |
| CN-114341162-A | Peptide conjugates of cytotoxins as therapeutic agents | 赛博克萨2公司 | 2022-04-12 | — | — | CN | disclosed |
| US-20210009719-A1 | PEPTIDE CONJUGATES OF CYTOTOXINS AS THERAPEUTICS | Cybrexa 2, Inc. | 2021-01-14 | — | — | US | disclosed |
| WO-2021007435-A1 | PEPTIDE CONJUGATES OF CYTOTOXINS AS THERAPEUTICS | Cybrexa 2, Inc. (US) | 2021-01-14 | — | — | WO | disclosed |
| WO-2021007435-A1 | PEPTIDE CONJUGATES OF CYTOTOXINS AS THERAPEUTICS | Cybrexa 2, Inc. (US) | 2021-01-14 | — | — | WO | disclosed |
| US-20210009719-A1 | PEPTIDE CONJUGATES OF CYTOTOXINS AS THERAPEUTICS | Cybrexa 2, Inc. | 2021-01-14 | — | — | US | disclosed |
| US-8759378-B2 | Methods for treating blood disorders | PHOENICIA BIOSCIENCES, INC. (US) | 2014-06-24 | — | — | US | disclosed |
| US-8759378-B2 | Methods for treating blood disorders | PHOENICIA BIOSCIENCES, INC. (US) | 2014-06-24 | — | — | US | disclosed |
| US-8759378-B2 | Methods for treating blood disorders | PHOENICIA BIOSCIENCES, INC. (US) | 2014-06-24 | — | — | US | disclosed |
| US-20090137567-A1 | Methods for Treating Blood Disorders | HEMAQUEST PHARMACEUTICALS, INC. (US) | 2009-05-28 | — | — | US | disclosed |
| US-20090137567-A1 | Methods for Treating Blood Disorders | HEMAQUEST PHARMACEUTICALS, INC. (US) | 2009-05-28 | — | — | US | disclosed |
| EP-2023913-A2 | METHODS FOR TREATING BLOOD DISORDERS | Colorado State University Research Foundation (US) | 2009-02-18 | — | — | EP | disclosed |
| US-20080075692-A1 | prophylaxis of blood disorder such as sickle cell anemia, beta -thalassemia, neutropenia or thrombocytopenia, comprising administering carboxylic acids, that stimulates production of fetal hemoglobin, hematopoiesis, erythropoiesis, myelopoiesis and neutrophil production | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION | 2008-03-27 | — | — | US | disclosed |
| US-20080075692-A1 | prophylaxis of blood disorder such as sickle cell anemia, beta -thalassemia, neutropenia or thrombocytopenia, comprising administering carboxylic acids, that stimulates production of fetal hemoglobin, hematopoiesis, erythropoiesis, myelopoiesis and neutrophil production | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION | 2008-03-27 | — | — | US | disclosed |
| WO-2007133653-A2 | METHODS FOR TREATING BLOOD DISORDERS | HEMAQUEST PHARMACEUTICALS, INC. (US) | 2007-11-22 | — | — | WO | disclosed |
| WO-2007133653-A2 | METHODS FOR TREATING BLOOD DISORDERS | HEMAQUEST PHARMACEUTICALS, INC. (US) | 2007-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12410262-B2 | Peptide conjugates of cytotoxins as therapeutics | TOP1, TOP2A, TOP2B | CES2 2701/4885CES1 1112/4885BCAT2 1697/4885 |
| US-11634508-B2 | Peptide conjugates of cytotoxins as therapeutics | TOP1, TOP2A, TOP2B | CES2 2701/4885CES1 1112/4885BCAT2 1697/4885 |
| US-20240010755-A1 | PEPTIDE CONJUGATES OF CYTOTOXINS AS THERAPEUTICS | TOP1, TOP2A, TOP2B | CES2 2701/4885CES1 1112/4885BCAT2 1697/4885 |
| US-20090137567-A1 | Methods for Treating Blood Disorders | HBB, HBG1, HBG2 | CES2 156/4885CES1 579/4885BCAT2 1401/4885 |
| US-20210009719-A1 | PEPTIDE CONJUGATES OF CYTOTOXINS AS THERAPEUTICS | TOP1, TOP2A, TOP2B | CES2 2701/4885CES1 1112/4885BCAT2 1697/4885 |
| US-20080075692-A1 | prophylaxis of blood disorder such as sickle cell anemia, beta -thalassemia, neutropenia or thrombocytopenia, comprising administering carboxylic acids, that stimulates production of fetal hemoglobin, hematopoiesis, erythropoiesis, myelopoiesis and neutrophil production | HBG1, HBG2, HBB | CES2 2543/4885CES1 2068/4885BCAT2 132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.